Drive for generics sees Korea increasingly attractive to international pharma

31 Jul 2019

Korean companies are opening more facilities overseas and using CPhI Korea to look for new international partners.

Already home to more than 40 pharmaceutical multinationals, Korea is on course to become a global biotech and pharmaceutical hub by 2025, driven by the surge of international partnerships, biosimilars, an expansion in the export of finished formulations and a robust generics market.

Drive for generics sees Korea increasingly attractive to international pharma

In fact, South Korean President Moon Jae-in stated in May 2019 that the Government will help foster ‘the biotechnology and pharmaceutical sectors as the country's new economic growth drive’.

Emphasizing the shift in the country’s global reputation, provisional data from the CPhI Annual Report 2019 shows that Korea improved its scores across ‘API quality’, ‘growth potential’ and ‘innovation’, with ‘overall competitiveness’ rising by 9% in the last year.

The new findings are announced in the lead-up to CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – which will open its sixth edition at the Seoul COEX Convention and Exhibition Centre from 21-23 August 2019.

“The show is widely seen as a barometer of industry trends within the region and this year we expect to see an increase in international bio buyers looking for access to services, equipment and bio-solutions as well as domestic partners. In total, over 5000 attendees from more than 50 countries and more than 190 exhibitors will attend” commented Laura Murina, Brand Manager at Informa.

Korean pharmaceutical exports have become attractive due to competitive pricing in the generics market and, as a result, Korean companies are opening more facilities overseas and using CPhI Korea to look for new international partners. In fact, the Korea Trade-Investment Promotion Agency (KOTRA) is facilitating exhibitors to meet with overseas buyers selected by the Global Bio Pharma Plaza (GBPP) at the event.

Emphasizing the international nature of Korea’s growth in exports, the CPhI Korea Conference, an integral part of the event, will include sessions from the Thai FDA, the Japanese PMDA, the China Chamber of Commerce for Imports and Exports of Medicines and Health Products (CCCMHPIE), as well as the European Directorate for the Quality of Medicines. The agenda will include detailed analysis of international regulations, GMP, QbD, and comparative strategies for global market entry.

Murina, continued: “South Korea’s expanding generics market and changing regulations are driving more international companies towards local partnerships. One of the great added benefits of this event’s size and dynamics is that it allows attendees to have more in-depth and targeted meetings. The high quality of meetings means that they deliver a very high rate of partnership outcomes.”

Finally, to help international companies looking to enter the country, CPhI Korea is working with the Korea Pharmaceutical Traders Association (KPTA) to promote a Meet the Expert Programme, which is specifically designed to help international companies understand the complexities of the South Korean market.

Read More

Related news

Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

5 Aug 2019

Opportunities abound at CPhI MEA and experts anticipate regional generic companies acting as CMOs for international companies looking to enter the region.

Read more 
Huge CPhI & P-MEC China a direct result of surging manufacturing

Huge CPhI & P-MEC China a direct result of surging manufacturing

22 Jul 2019

Great Hall of China: Informa adds additional capacity to Asia’s largest pharma event with record 66,000+ visits from 141 countries.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Piramal expands its high potency API capability

Piramal expands its high potency API capability

25 Jun 2019

Becomes one of only a few companies in the contract development and manufacturing market that can produce HPAPIs at such low OELs.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
PASCOE Naturmedizin exhibits at CPhI Worldwide Exhibition in Frankfurt

PASCOE Naturmedizin exhibits at CPhI Worldwide Exhibition in Frankfurt

18 Jun 2019

PASCOE Naturmedizin is one of Germany's 100 most innovative medium-sized enterprises. The success story of our family’s specialist naturopathy company began three generations and almost 125 years ago when Friedrich H. Pascoe's first pharmacy in Mülh...

Read more 
Liquid pharmaceuticals in the digital age

Liquid pharmaceuticals in the digital age

30 May 2019

Inspiration, innovation and technical highlights from Bosch Packaging Technolgy's Pharmatag 2019.

Read more 
CPhI China opens with analysis pointing to a surge in growth in 2019

CPhI China opens with analysis pointing to a surge in growth in 2019

28 May 2019

Regulatory reforms and harmonisation reported as key drivers of industry in China.

Read more 
Expert forecasts huge growth in Middle East manufacturing

Expert forecasts huge growth in Middle East manufacturing

16 May 2019

UAE consumers and insurance companies are willing to pay for highest quality drug products.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more